BMC Cancer 2007, 7:226 http://www.biomedcentral.com/1471-2407/7/226 Table 2: Occurrence of most common imbalances in different epithelial neoplasias by CGH Regional imbalance Most frequent* Above background Putative targets** Breast, ovary, HCC, cervix, NPC, MEL, endometrial, vulva Gastric, CRC, HCC, HNSCC, NSCLC, ES, RCC, bladder, PAC, SCLC, SQS HNSCC, NSCLC, cervix, ES, RCC, NE, MEL (whole chr. 3), SCLC, vulva, SQS Ovary, HNSCC, NSCLC, cervix, ES, NPC, SCLC, endometrial, vulva, SQS Gastric, PAC Gastric, RCC, PAC ABL2, ETV3 FHIT, MLH1 BCL6, PIK3CA PRDM5 CDH6, TERT APC, MCC E2F3, ID4 CCNC 7p: EGFR 7q: ABCB1, MET DLC1, MSR1, N33 MYC ARF, CDKN2A CCND1, FGF3 ATM (11q22), (LOH11CR2 A, TSG11) 12p: CDK2, CDK4, GLI, KRAS 12q: MDM2 dim(4q) Ovary, HCC, NSCLC, cervix, ES, bladder, frequently whole chromosome cholangio, SCLC enh(1q) occuring in most carcinoma types dim(3p) enh(3q) maxima at 3q26q27 (except 3q25 in NPC) enh(5p) dim(5q) enh(6p) dim(6q) maxima at 6q16q21 or 6q24q27 enh(7) frequently whole 7, mostly max. on 7q dim(8p) enh(8q) ubiquitously high (exception NE and thyroid) dim(9p) 9p or whole 9 enh(11q13) frequently distinct (high-level) gain dim(11q23qter) enh(12p) frequently whole 12; slight max. on 12p dim(13q) mostly 13q14q21 dim(16q) dim(17p) enh(17q) dim(18q) enh(19q) enh(20q) Thyroid, NSCLC, cervix, Ovary, NSCLC, HCC, MEL Prostate, RCC, MEL Prostate, thyroid, ES, RCC Breast, prostate, CRC, HCC Breast, prostate, ovary, CRC, HCC, HNSCC, NSCLC, ES, RCC, bladder, MEL, PAC, cholangio, endometrial, vulva HNSCC, bladder, PAC, SQS HNSCC NPC, NE, vulva NPC Gastric, CRC, HNSCC, RCC, PAC, Gastric, ovary, CRC, HCC, HNSCC, ES, bladder, NE, PAC, cholangio, vulva Prostate, gastric, HNSCC, ES, bladder, cholangio, Ovary, NSCLC, cervix, ES, bladder, cholangio, SCLC, vulva Ovary, HCC, NSCLC, cervix, bladder, NE, PAC, cholangio, SCLC Gastric, ovary, CRC, HCC, HNSCC, bladder, MEL, PAC (7p>7q), cholangio (7p>7q) Ovary, HNSCC, NSCLC, ES, RCC, bladder, PAC, SCLC, vulva Cervix, NPC, SCLC, SQS Gastric, NSCLC, ES, RCC, NPC, MEL, SCLC Breast, gastric, ovary, NSCLC, ES, NPC, bladder, MEL, PAC, cholangio Breast, HNSCC, cervix, ES, MEL, SCLC Ovary, CRC, HNSCC, NSCLC, ES, RCC, PAC, vulva Prostate, HCC, thyroid, bladder, NE, PAC, SCLC, endometrial Breast, NPC Breast, gastric, CRC, cholangio, SCLC Breast, gastric, bladder, NE, PAC, cholangio, SCLC, SQS Gastric, ovary, CRC, HNSCC, PAC, SQS NE, SCLC Gastric, CRC, thyroid, bladder, NE, PAC, cholangio Breast, gastric, ovary, HNSCC, NSCLC, BRCA2, RB1, STARD13 cervix, ES, RCC, NPC (max. at 13q31), MEL, CRC, vulva Prostate, gastric, HCC, SCLC CDH1, ATBF1 Ovary, HCC, NSCLC, cervix, ES, RCC, TP53 NPC, bladder, PAC, SQS HCC, HNSCC, NSCLC, cervix, ES, renal, ERBB2 NPC HCC, NSCLC, cervix, renal, bladder, DCC, SMAD4 cholangio Breast, CRC, PAC, vulva AKT2, BAX Breast, HCC, cervix, ES, renal, MEL, SCLC, STK15/AuroraA vulva Please refer to table 1 for abbreviations. * "most frequent" lists entities in which the aberration belongs to the 3 most frequent imbalances of the specified quality (enh = gain, dim = loss; bold if most frequent change in entity). Entities are sorted according to the total number of included cases. Chromosomal regions 1p, 21, 22, X and Y were omitted due to differences in reporting (e.g. exclusion of regions prone to errors in chromosomal CGH analysis). ** Listed are some examples of genes with oncogene (for gain regions) or tumor suppressor (for loss regions) function. However, a large number of possible target genes as well as structural features may exist for each region. Ovarian carcinoma (449 cases) Gains: 8q24 (43.7%), 3q26 (38.1%), 1q32 (25.3%), 12p12 (19.2%), 2, 5p, 6p, 7q, 11(q13) Losses: 5q14 (25.2%), 4q (26.3%), 18q21 (19.8%), 17p (19.6%), 8p (19.4%), 6q, 9q, 13q, 16q, X ity. Gains on 12p have been discussed as early event in ovar- ian carcinomas with frequent occurrence in borderline tumors [50], and several other changes have been linked to advanced carcinomas [51]. Overall, advanced stage tumors showed a higher grade of chromosomal instabil- Page 5 of 15 (page number not for citation purposes)